SU 65847

Drug Profile

SU 65847

Latest Information Update: 02 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SUGEN
  • Class Antineoplastics; Isoxazoles; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 21 Sep 1999 SUGEN has been acquired by Pharmacia & Upjohn
  • 09 Sep 1998 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top